Robert Azelby has sold JUNO and made no open-market buys since Nov 2016

Azelby Robert is a person and biopharmaceutical executive with more than 30 years of industry experience, including leadership in oncology commercialization, corporate strategy, and company building.( He served as Executive Vice President and Chief Commercial Officer of Juno Therapeutics from November 2015 until Juno’s acquisition in 2018, where he was responsible for commercial leadership at the cancer-focused biopharmaceutical company.(

Before Juno, Azelby spent 15 years at Amgen, holding senior roles including Vice President and General Manager of the Oncology Business Unit, Vice President of U.S. Oncology Sales, Vice President of the North American Commercial Effectiveness Unit, and General Manager of Amgen Netherlands.( He later became CEO of Alder BioPharmaceuticals from 2018 to 2019 and CEO of Eliem Therapeutics from 2020 to 2023, and he currently serves as a board director for several public biotech and healthcare companies, including ADC Therapeutics, Autolus Therapeutics, Cardinal Health, and Terns Pharmaceuticals.( Azelby earned a B.A. in Economics and Religious Studies from the University of Virginia and an MBA from Harvard Business School.(

Written by Perplexity from public sources.